Alivus Life Sciences announced its Q4 FY26 results with steady growth in revenue and profitability on a year-on-year basis. The company reported higher operating income and improved annual earnings during the quarter ended March 31, 2026.
For the March 2026 quarter, revenue from operations rose 6.3% YoY to ₹689.1 crore compared to ₹649.5 crore in the corresponding quarter last year.
The company posted a net profit of ₹162.7 crore in Q4 FY26, up 14.7% from ₹141.9 crore reported in Q4 FY25.
Total income during the quarter increased 7.9% YoY to ₹711.9 crore against ₹659.6 crore in the year-ago period.
Profit before tax (PBT) stood at ₹215.8 crore for the quarter, registering a growth of 12.8% compared to ₹191.3 crore in the same quarter previous year.
Employee benefit expenses came in at ₹78.1 crore versus ₹66.7 crore YoY, while other expenses rose to ₹125.6 crore from ₹101.8 crore.
On the operational front, total expenses for the quarter increased to ₹496.1 crore as against ₹468.3 crore in Q4 FY25.
Alivus Life Sciences FY26 Performance
For the full financial year FY26, Alivus Life Sciences reported revenue from operations of ₹2,551.8 crore, up 6.9% from ₹2,386.9 crore in FY25.
Annual net profit rose 16.2% YoY to ₹564.5 crore compared to ₹485.6 crore in the previous financial year.
Profit before tax for FY26 stood at ₹751.3 crore, rising 14.9% against ₹654.1 crore reported in FY25.
Total income for the year increased to ₹2,612.2 crore from ₹2,421.5 crore in FY25.
The company also reported total tax expenses of ₹186.8 crore for FY26 compared to ₹168.5 crore in the previous year.